[go: up one dir, main page]

CA2504611A1 - Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique - Google Patents

Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique Download PDF

Info

Publication number
CA2504611A1
CA2504611A1 CA002504611A CA2504611A CA2504611A1 CA 2504611 A1 CA2504611 A1 CA 2504611A1 CA 002504611 A CA002504611 A CA 002504611A CA 2504611 A CA2504611 A CA 2504611A CA 2504611 A1 CA2504611 A1 CA 2504611A1
Authority
CA
Canada
Prior art keywords
amount
daunorubicin
days
cytarabine
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504611A
Other languages
English (en)
Inventor
Jay Marshall Feingold
Matthew L. Sherman
Lance H. Leopold
Mark Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2504611A1 publication Critical patent/CA2504611A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des méthodes thérapeutiques et des combinaisons pharmaceutiques de traitement de leucémies aiguës telles que la leucémie myélogène aiguë ou le syndrome myélodysplasique, utilisant un conjugué cytotoxique anti-CD33 associé à au moins un composé choisi parmi l'anthracycline, ou un analogue de nucléoside de la pyrimidine ou de la purine. Les méthodes thérapeutiques et combinaisons pharmaceutiques préférées utilisent la gemtuzumab ozogamicine, la daunorubicine, et la cytarabine.
CA002504611A 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique Abandoned CA2504611A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (fr) 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique

Publications (1)

Publication Number Publication Date
CA2504611A1 true CA2504611A1 (fr) 2004-05-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504611A Abandoned CA2504611A1 (fr) 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique

Country Status (10)

Country Link
EP (1) EP1575582A4 (fr)
JP (1) JP2006508119A (fr)
CN (1) CN1720044A (fr)
AU (2) AU2002348178A1 (fr)
BR (1) BR0215935A (fr)
CA (1) CA2504611A1 (fr)
CR (1) CR7804A (fr)
MX (1) MXPA05004711A (fr)
NO (1) NO20052009L (fr)
WO (1) WO2004043461A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (fr) * 2004-10-29 2006-05-11 Regents Of The University Of California Methode visant a accroitre l'elimination des cellules tumorales a l'aide de combinaisons d'agents antineoplasiques
EP1661584A1 (fr) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation
EP1898946A1 (fr) * 2005-07-06 2008-03-19 Kanisa Pharmaceuticals, Inc. Traitement de patients atteints de cancer à l'aide d'un conjugué de calicheamicine et d'anticorps en combinaison avec du zosuquidar
EP1859811B1 (fr) * 2006-05-27 2011-08-24 Faulstich, Heinz, Dr. Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
JP5314600B2 (ja) * 2007-02-16 2013-10-16 セラター・ファーマスーティカルズ・インコーポレーテッド 造血器癌および増殖性疾患の治療のための固定した薬物比
CA2708264C (fr) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Procedes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphtyridine-3-carboxylique pour le traitement de troubles hematologiques anterieurs
EP2333108A4 (fr) 2008-08-29 2012-05-09 School Juridical Person The Kitasato Inst Méthode de détection des effets sur des médicaments des inhibiteurs de méthylation de l'adn
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
EP3442584B1 (fr) 2016-03-15 2021-07-28 Seagen Inc. Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2
WO2017210621A1 (fr) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combinaison de conjugués anticorps cd33 médicament avec des agents chimiothérapeutiques
EP3469001A4 (fr) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
UA126920C2 (uk) * 2017-06-22 2023-02-22 Ле Лаборатуар Сервьє Комбінація інгібітору mcl-1 і стандартного лікарського препарату для лікування гематологічних злоякісних новоутворень, її застосування та фармацевтичні композиції, що її містять
CA3069558A1 (fr) * 2017-07-09 2019-01-17 Biosight Ltd. Polytherapie anticancereuse
CN113631193A (zh) * 2019-01-28 2021-11-09 德州大学系统董事会 用于治疗癌症的金属螯合剂组合疗法
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
US20240000846A1 (en) * 2020-10-27 2024-01-04 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2418014C (fr) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapie destine a traiter la leucemie myelocytique chronique

Also Published As

Publication number Publication date
AU2010201113A1 (en) 2010-04-15
EP1575582A1 (fr) 2005-09-21
JP2006508119A (ja) 2006-03-09
NO20052009D0 (no) 2005-04-25
CN1720044A (zh) 2006-01-11
EP1575582A4 (fr) 2009-03-11
BR0215935A (pt) 2005-08-09
AU2002348178A1 (en) 2004-06-03
MXPA05004711A (es) 2005-08-03
WO2004043461A1 (fr) 2004-05-27
NO20052009L (no) 2005-06-27
CR7804A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
US7727968B2 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU2010201113A1 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
Ho et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Fleischhack et al. IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
CN110869029A (zh) 组合癌症治疗
CZ20003493A3 (cs) Protinádorová kompozice obsahující synergicky působící kombinaci derivátu anthracyklinu s derivátem kamptotecinu
Lee et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia
RU2338535C2 (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластического синдрома
Case Jr et al. Phase I–II trial of high-dose Epirubicin in patients with lymphoma
Lopez et al. Oral idarubicin in non-Hodgkin's lymphomas
Frenette et al. Granulocyte‐macrophage colony stimulating factor (GM‐CSF) priming in the treatment of elderly patients with acute myelogenous leukemia
Bakker et al. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients
Case Jr et al. Phase II study of aclarubicin in acute myeloblastic leukemia
Robak et al. Older and new formulations of cladribine: pharmacology and clinical efficacy in hematological malignancies
Lalhmangaihzuala et al. Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
CN101259129A (zh) 急性白血病和骨髓异常增生综合征的组合治疗
Paciucci et al. Sequential intermediate‐dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia
Parikh et al. High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study
Reiser et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma
Herzig et al. High‐dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six‐day regimens
Thomas et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia
Saşmaz et al. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia
Larrea et al. Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia
WO1993021938A1 (fr) Procedes de traitement du cancer au moyen de l'epirubicine a haute dose
Horikoshi et al. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead